| Bioactivity | TRC-766 is a negative control of RTC-5 (TRC-382). TRC-766 binds protein phosphatase 2A (PP2A) and does not activate the phosphatase[1]. | ||||||||||||
| Invitro | As a pharmacologic control, the cells are treated with increasing doses of TRC-766, which is structurally similar to PP2A (SMAP) but biologically inactive. TRC-766 lacks a key N-H sulfonamide hydrogen bond donor. While TRC-766 still binds PP2A, it does not activate the phosphatase and therefore it was postulated to not affect cell viability[1]. | ||||||||||||
| Name | TRC-766 | ||||||||||||
| CAS | 1810734-44-1 | ||||||||||||
| Formula | C25H24ClF3N2O3S | ||||||||||||
| Molar Mass | 524.98 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Kimberly McClinch, et al. Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer. Cancer Res. 2018 Apr 15;78(8):2065-2080. |
TRC-766
CAS: 1810734-44-1 F: C25H24ClF3N2O3S W: 524.98
TRC-766 is a negative control of RTC-5 (TRC-382). TRC-766 binds protein phosphatase 2A (PP2A) and does not activate the
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.